Elon Musk Just Shared Bad News for Intel Shareholders

Elon Musk confirmed a report that Terafab is in talks with TSMC, raising uncertainty about Intel's role in the joint venture; Intel had appeared positioned as its manufacturing partner. Intel's foundry business reported $5.8 billion in revenue last quarter, up 31% year over year, but $5.5 billion came from Intel's own chipmaking, underscoring its need for external customers. Intel's 14A process is scheduled for risk production next year and volume production in 2028; the article notes Intel shares are up 163% since early April and trade at 63 times forward earnings estimates.

Analysis

The key market question is not whether TSMC participates, but which work Terafab awards—and whether it becomes a funded, high-volume customer at all. A split arrangement could leave Intel with some manufacturing work while shifting advanced packaging or process support to TSMC; that would dilute the clean “anchor customer” narrative without necessarily eliminating Intel’s opportunity. Conversely, a TSMC-led wafer award would weaken the external validation Intel needs to support its foundry investment case. Neither outcome is yet established: talks and technical interest are not equivalent to a signed commitment, qualified process, or profitable utilization.

Near term, INTC is vulnerable to expectation compression if investors had priced Terafab as exclusive validation of 14A. Over 1–3 months, watch for the actual division of wafer production, packaging, and engineering responsibilities, alongside customer engagement after Intel’s PDK release. Over 6–18 months, design wins, process qualification, customer funding, and utilization matter more than headline partnership language. TSMC could gain incremental Texas utilization and strategic backing, but new capacity also carries execution and capital-intensity risk; the article does not establish that Terafab would materially change its economics.

Contrarian angle: TSMC’s involvement may validate Terafab’s scale ambitions rather than prove Intel is technically uncompetitive. Intel’s downside is greatest if the project was its only credible external 14A prospect; verify the broader customer pipeline before treating this as a thesis break.

Key Decisions for Investors

• Do not chase INTC on partnership headlines; treat any weakness as a catalyst-driven repricing risk while the work split and funding remain unconfirmed.
• Watch for a signed Terafab agreement specifying wafer volumes, process node, packaging scope, and who funds capacity. A TSMC-led wafer award with Intel limited to ancillary work would strengthen the relative short-INTC/long-TSM thesis; a substantial Intel 14A wafer commitment would falsify it.
• For a relative-value position, consider short INTC versus long TSM only after evidence of a TSMC-primary manufacturing award. Keep sizing modest: TSMC’s capex burden and the possibility of a genuinely split award weaken the trade before confirmation.
• Track Intel’s post-PDK external design wins, 14A risk-production schedule, and customer-backed capacity plans. If these advance independently of Terafab, the market may be over-discounting this negotiation; if they stall, the foundry concern becomes more structural.